GRI Bio, Inc. (GRI): Cash & Equivalents
$8.23M
As of 2025-12-31
$10.95M
As of 2026-06-30
n/m
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.23M | +63.7% | 2026-01-30, Balance as of period end |
| 2024-12-31 | $5.03M | +178.1% | 2026-01-30, Balance as of period end |
| 2023-12-31 | $1.81M | n/m | 2025-03-14, Balance as of period end |
| 2022-12-31 | $9.0K | -99.8% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $3.70M | n/m | 2023-02-24, Balance as of period end |
| 2020-12-31 | $109.0K | n/a | 2022-02-14, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| GRI Bio, Inc. (GRI) | 2025-12-31 | $8.23M | +63.7% |
| CNS Pharmaceuticals, Inc. (CNSP) | 2025-12-31 | $7.20M | +11.4% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $405.0K | -66.2% |
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | $1.56M | -67.5% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $796.8K | -45.9% |
| Revium Rx. (RVRC) | 2025-12-31 | $1.68M | -48.7% |
| Lunai Bioworks Inc. (LNAI) | 2025-06-30 | $92.7K | -58.0% |
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | $6.12M | -54.0% |
| GT Biopharma, Inc. (GTBP) | 2025-12-31 | $6.81M | +72.4% |
Compare GRI, CNSP, IGC, NNVC side by side · Screen every company in Pharmaceutical Preparations ↗